SCHEMBL5610086

SCHEMBL5610086

CSc1ccc2ccccc2c1[O]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ CYP2A6 P11509 3/20 0.44
▸ TSHR P16473 3/20 0.44
▸ HSD17B10 Q99714 3/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ HPRT1 P00492 1/20 0.41
▸ CYP1A2 P05177 1/20 0.39
▸ PAX8 Q06710 1/20 0.39
▸ KMT2A Q03164 1/20 0.38
▸ HIF1A Q16665 2/20 0.38
▸ CYP1B1 Q16678 1/20 0.38
▸ POLB P06746 1/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ PKM P14618 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ USP2 O75604 1/20 0.35
▸ PAK1 Q13153 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11908113 0.80 CYP2A6 (0.50) SLC2A1ALDH1A1CYP2A6TSHRHSD17B10
SCHEMBL5609776 0.79 ELANE (0.41) SLC2A1ALDH1A1CYP2A6TSHRHSD17B10
SCHEMBL31038169 0.78 ALDH1A1 (0.48) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL385875 0.78 ALDH1A1 (0.48) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL31323067 0.78 ALDH1A1 (0.48) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL8048298 0.78 IFNAR1 (0.49) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL1057369 0.77 CYP2A6 (0.46) SLC2A1ALDH1A1CYP2A6TSHRHSD17B10
SCHEMBL13021634 0.77 TSHR (0.56) SLC2A1ALDH1A1CYP2A6TSHRHSD17B10
SCHEMBL30357700 0.77 CYP2A6 (0.46) SLC2A1ALDH1A1CYP2A6TSHRHSD17B10
SCHEMBL7479415 0.76 SIRT1 (0.42) ALDH1A1CYP2A6TSHRHSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020071470-A1 PHTHALOCYANINE COMPOUND AND USE THEREOF 山本化成株式会社 2020-04-09 — — WO disclosed
US-7199139-B2 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2007-04-03 — — US disclosed
EP-1354602-B1 MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT SANKYO CO (JP) 2006-10-04 — — EP disclosed
EP-1695716-A2 Medicinal compositions containing diuretics and insulin sensitizers Sankyo Company, Limited (JP) 2006-08-30 — — EP disclosed
US-20050288339-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2005-12-29 — — US disclosed
US-20040053974-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2004-03-18 — — US disclosed
US-20040006141-A1 Amidocarboxylic acid compounds SANKYO COMPANY, LTD (JP) 2004-01-08 — — US disclosed
EP-1354602-A1 MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT Sankyo Company, Limited (JP) 2003-10-22 — — EP disclosed
US-6528525-B1 Amidocarboxylic acid derivatives SANKYO COMPANY, LIMITED (JP) 2003-03-04 — — US disclosed
EP-0818512-B1 Quinoline derivative and use of same MITSUI CHEMICALS INC (JP) 2002-10-02 — — EP disclosed
US-6407242-B1 REACTING A PHTHALIMIDE COMPOUND WITH A QUINOLINE COMPOUND;ELECTROLUMINESCENCE MITSUI CHEMICALS, INC. (JP) 2002-06-18 — — US disclosed
US-6132640-A ZINC COMPLEXES OF QUINOLINE MITSUI CHEMICALS, INC. (JP) 2000-10-17 — — US disclosed
US-6106999-A SENSITIVITY TO GENERAL-PURPOSE VISIBLE LIGHT LASER, SO THAT HIGH-SPEED SCANNING EXPOSURE IS POSSIBLE BY LASER, AND EXTREMELY FINE HIGH RESOLUTION CAN BE OBTAINED; CAN BE USED FOR COATING OR PRINTING UNDER SAFELIGHT IRRADIATING CONDITIONS MITSUI CHEMICALS (JP) 2000-08-22 — — US disclosed
EP-1026149-A1 AMIDOCARBOXYLIC ACID DERIVATIVES Sankyo Company Limited (JP) 2000-08-09 — — EP disclosed
EP-0818512-A1 Quinoline derivative and use of same MITSUI TOATSU CHEMICALS, Inc. (JP) 1998-01-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053974-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent GPR119, INSR, IRS1 SLC2A1 17/4885ALDH1A1 2128/4885CYP2A6 3649/4885
US-20040006141-A1 Amidocarboxylic acid compounds NR1H2, AGK, APOL1 SLC2A1 111/4885ALDH1A1 3508/4885CYP2A6 769/4885
US-20050288339-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent GPR119, INSR, IRS1 SLC2A1 17/4885ALDH1A1 2128/4885CYP2A6 3649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback